Ramalingam Vijay, Yang Lauren M, McCarthy Colin J, Ahmed Muneeb
Division of Vascular and Interventional Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Division of Hepatology and Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Life (Basel). 2023 May 26;13(6):1262. doi: 10.3390/life13061262.
Porto-mesenteric vein thrombosis (PVT) is a well-recognized but uncommon disease entity in patients with and without cirrhosis. Given the complexity of these patients, there are many differing treatment algorithms depending on the individual circumstances of a given patient. The focus of this review is primarily patients with cirrhosis, with an emphasis on liver transplantation considerations. The presence of cirrhosis substantially affects work-up, prognosis, and management of these patients and will substantially affect the patient treatment and have additional implications for prognosis and long-term outcomes. Here, we review the incidence of portal vein thrombosis in known cirrhotic patients, medical and interventional treatment options that are currently used, and, in particular, how to approach cirrhotic patients with PVT who are awaiting liver transplantation.
门静脉肠系膜静脉血栓形成(PVT)在肝硬化和非肝硬化患者中是一种已得到充分认识但并不常见的疾病实体。鉴于这些患者情况复杂,根据特定患者的个体情况,有许多不同的治疗方案。本综述的重点主要是肝硬化患者,尤其侧重于肝移植相关考量。肝硬化的存在会极大地影响这些患者的检查、预后及管理,还会对患者治疗产生重大影响,并对预后和长期结局有额外意义。在此,我们回顾已知肝硬化患者门静脉血栓形成的发生率、目前使用的药物和介入治疗选择,特别是如何处理等待肝移植的肝硬化合并PVT患者。